Actively Recruiting

Age: 18Years - 65Years
All Genders
ID04251143

Dresden Corneal Disease and Treatment Study - Quality Analysis of Follow-up and Treatments for Corneal Diseases at University Hospital Carl Gustav Carus Dresden

Led by Technische Universität Dresden · Updated on 2023-02-28

700

Participants Needed

1

Research Sites

260 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to follow patients with corneal diseases, particularly corneal ectasia such as keratoconus, to analyze the quality of surgical treatments and diagnosis over the long term. Keratoconus causes the cornea to become steeper, thinner, and irregular, leading to irreversible vision loss. Surgical interventions like corneal cross-linking are performed if the disease progresses, making long-term monitoring essential to detect early disease changes and confirm treatment stability. Participants may undergo diagnostic tests including corneal topography and tomography for detailed assessment. The study focuses on observing the natural course and treatment outcomes over 15 years, including postoperative follow-ups. Various eye examinations and measurements are performed, such as anterior optical coherence tomography, Scheimpflug-based tomography, biomechanical assessments, optical biometry, confocal microscopy, and endothelium cell counts. During the study, participants will have regular evaluations of their corneal condition and treatment effects. Researchers collect data on factors like age, sex, family history, previous surgeries, and medications. The main outcomes measured are follow-up intervals and postoperative follow-up intervals over 15 years, as well as assessment of treatment quality. Participants can expect ongoing monitoring to understand disease progression and treatment success throughout the study period.

CONDITIONS

Brief Title

Dresden Corneal Disease and Treatment Study

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of corneal disease
  • Diagnosis of corneal ectasia
Not Eligible

You will not qualify if you...

  • Pregnancy
  • Age under 18 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Monitoring

Duration - Up to 15 years

Participants undergo regular examinations including corneal topography and tomography to monitor progression of corneal ectasia and assess treatment success.

Trial Site Locations

Total: 1 location

1

Department of Ophthalmology; Medical Faculty Carl Gustav Carus; Technical University Dresden

Dresden, Saxony, Germany, 01307

Actively Recruiting

Loading map...

Research Team

R

Robert Herber, MSc

J

Janine Lenk, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

Safety and Clinical Activity Study of Belantamab Mafodotin W...

Multiple Myeloma

Actively Recruiting

2 locations

Application of Deep Learning for Screening Multiple Corneal ...

Deep Learning

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Comparison of corneal tomography using a novel swept-source optical coherence tomographer and rotating Scheimpflug system in normal and keratoconus eyes: repeatability and agreement analysis.

Robert Herber, Janine Lenk, Lutz E Pillunat...

https://pubmed.ncbi.nlm.nih.gov/35606839

Development of a classification system based on corneal biomechanical properties using artificial intelligence predicting keratoconus severity.

Robert Herber, Lutz E Pillunat, Frederik Raiskup

https://pubmed.ncbi.nlm.nih.gov/34059127